Graham Richard Law

Graham Richard Law

Auto-generated profile, based on publicly available information

Graham Richard Law

University of Leeds

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2002 in Blood
Verified
Journal Article
Closed access
PDF file
CSChristine F. Skibola
Christine F. Skibola
MSMartyn T. Smith
Martyn T. Smith
AHAlan Hubbard
Alan Hubbard
BSBarry Shane
Barry Shane
ARAbby C. Roberts
Abby C. Roberts
GMGareth John Morgan
Gareth John Morgan
We previously reported that 2 polymorphisms in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene at positions C677T and A1298C were associated with lower risk of adult acute lymphocytic leukemia (ALL). In the present study, we have examined whether polymorphisms in other folate-metabolizing genes play a role in ALL susceptibility. Polymorphisms in methionine synthase (MS A2756G), cytosolic serine hydroxymethyltransferase (SHMT1 C1420T), and a double (2R2R) or triple (3R3R) 28-bp tandem repeat in the promoter region of thymidylate synthase (TS) were studied and found to modulate ALL risk. In a univariate analysis, SHMT1 1420CT individuals exhibited a 2.1-fold decrease in ALL risk (odds ratio [OR] = 0.48; 95% confidence interval [CI], 0.25-0.91), whereas the 1420TT genotype conferred a 3.3-fold reduction in risk (OR = 0.31; 95% CI, 0.10-0.90). Similarly, TS 2R3R individuals exhibited a 2.8-fold reduction in ALL risk (OR = 0.36; 95% CI: 0.16-0.83), while the TS 3R3R genotype conferred an even greater level of protection (OR = 0.25; 95% CI, 0.08-0.78). However, no significant associations were evident for the MS 2756AG polymorphism (OR = 0.79; 95% CI, 0.38-1.7). In addition, potential interactions between theSHMT1 and TS or MS genes were observed. TS 3R3R individuals who were SHMT1 1420CT/TT had a 13.9-fold decreased ALL risk (OR = 0.072; 95% CI, 0.0067-0.77). Further, MS 2756AG individuals who were SHMT1 1420CT/TT had a 5.6-fold reduction in ALL risk (OR = 0.18; 95% CI, 0.05-0.63). This study suggests an important role for uracil misincorporation and resultant chromosomal damage in the pathogenesis of ALL, and that genetic interactions involving low penetrance polymorphisms in folate-metabolizing genes may increase ALL risk.

1 December 1999 in The Lancet
Verified
Journal Article
Closed access
KCKk Cheng
Kk Cheng
NDN Day
N Day
RCR Cartwright
R Cartwright
ACA Craft
A Craft
JBJm Birch
Jm Birch
UIUkccs Investigat
Ukccs Investigat

23 April 2015 in Diabetes Care
Verified
Journal Article
Open access
PDF file
GLGraham R. Law
Graham R. Law
GEGeorge Ellison
George Ellison
ASAnna L. Secher
Anna L. Secher
PDPeter Damme
Peter Damme
EMElisabeth Mathiesen
Elisabeth Mathiesen
ESEleanor M. Scott
Eleanor M. Scott
OBJECTIVE: Continuous glucose monitoring (CGM) is increasingly used to assess glucose control in diabetes. The objective was to examine how analysis of glucose data might improve our understanding of the role temporal glucose variation has on large-for-gestational-age (LGA) infants born to women with diabetes. RESEARCH DESIGN AND METHODS: Functional data analysis (FDA) was applied to 1.68 million glucose measurements from 759 measurement episodes, obtained from two previously published randomized controlled trials of CGM in pregnant women with diabetes. A total of 117 women with type 1 diabetes (n = 89) and type 2 diabetes (n = 28) who used repeated CGM during pregnancy were recruited from secondary care multidisciplinary obstetric clinics for diabetes in the U.K. and Denmark. LGA was defined as birth weight ≥90th percentile adjusted for sex and gestational age. RESULTS: A total of 54 of 117 (46%) women developed LGA. LGA was associated with lower mean glucose (7.0 vs. 7.1 mmol/L; P < 0.01) in trimester 1, with higher mean glucose in trimester 2 (7.0 vs. 6.7 mmol/L; P < 0.001) and trimester 3 (6.5 vs. 6.4 mmol/L; P < 0.01). FDA showed that glucose was significantly lower midmorning (0900–1100 h) and early evening (1900–2130 h) in trimester 1, significantly higher early morning (0330–0630 h) and throughout the afternoon (1130–1700 h) in trimester 2, and significantly higher during the evening (2030–2330 h) in trimester 3 in women whose infants were LGA. CONCLUSIONS: FDA of CGM data identified specific times of day that maternal glucose excursions were associated with LGA. It highlights trimester-specific differences, allowing treatment to be targeted to gestational glucose patterns.

1 April 2010 in Gastroenterology
Verified
Journal Article
Closed access
RZRocco Maurizio Zagari
Rocco Maurizio Zagari
GLGraham Richard Law
Graham Richard Law
LFLorenzo Fuccio
Lorenzo Fuccio
VCVincenzo Cennamo
Vincenzo Cennamo
MGMark S. Gilthorpe
Mark S. Gilthorpe
FBFranco Bazzoli
Franco Bazzoli

24 April 1997 in Diabetologia
Verified
Journal Article
Closed access
PDF file
RPR. C. Parslow
R. C. Parslow
PMP. A. McKinney
P. A. McKinney
GLG. R. Law
G. R. Law
ASAnthony Staines
Anthony Staines
RWR. Williams
R. Williams
HBH. J. Bodansky
H. J. Bodansky

1 March 2000 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
PMP. A. McKinney
P. A. McKinney
MOM. Okasha
M. Okasha
RPR. C. Parslow
R. C. Parslow
GLG. R. Law
G. R. Law
KGK. A. Gurney
K. A. Gurney
HBH. J. Bodansky
H. J. Bodansky